|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400092346 |
|
最近更新日期: Date of Last Refreshed on: |
2024-11-14 14:58:37 |
|
注册时间: Date of Registration: |
2024-11-14 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
基于肌筋膜触发点理论探究其在原发性痛经中的治疗效果及作用机制 |
|
Public title: |
Exploring the Therapeutic Effect and Mechanism of Myofascial Trigger Points Theory in Primary Dysmenorrhea |
|
注册题目简写: |
肌筋膜触发点治疗原发性痛经的效果与神经机制研究 |
|
English Acronym: |
The Effectiveness and Mechanisms of Myofascial Trigger Point Therapy in the Treatment of Primary Dysmenorrhea |
|
研究课题的正式科学名称: |
肌筋膜触发点治疗原发性痛经的临床疗效及神经肌肉机制研究 |
|
Scientific title: |
Myofascial trigger point in the treatment of primary dysmenorrhea and neuromuscular mechanism |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
陈兴利 |
研究负责人: |
陈兴利 |
|
Applicant: |
Xingli Chen |
Study leader: |
Xingli Chen |
|
申请注册联系人电话: Applicant telephone: |
+86 188 1783 8092 |
研究负责人电话: Study leader's telephone: |
+86 155 5055 9812 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
dsnever@163.com |
研究负责人电子邮件: Study leader's E-mail: |
dsnever@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市杨浦区清源环路 |
研究负责人通讯地址: |
上海市杨浦区清源环路 |
|
Applicant address: |
Qingyuan Ring Road, Yangpu District, Shanghai |
Study leader's address: |
Qingyuan Ring Road, Yangpu District, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
上海市杨浦区中心医院(同济大学附属杨浦医院) |
||
|
Applicant's institution: |
Shanghai Yangpu District Central Hospital (Tongji University Affiliated Yangpu Hospital) |
||
|
研究负责人所在单位: |
上海市杨浦区中心医院(同济大学附属杨浦医院) |
||
|
Affiliation of the Leader: |
Shanghai Yangpu District Central Hospital (Tongji University Affiliated Yangpu Hospital) |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
LL-2022-WSJ-007 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
杨浦区中心医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Yangpu District Central Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-07-08 00:00:00 |
||
|
伦理委员会联系人: |
王海鹰 |
||
|
Contact Name of the ethic committee: |
Wang Haiying |
||
|
伦理委员会联系地址: |
上海市杨浦区腾跃路 |
||
|
Contact Address of the ethic committee: |
Tengyue Road, Yangpu District, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 6550 8161 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
lunli@sus.edu.cn |
|
研究实施负责(组长)单位: |
上海市杨浦区中心医院(同济大学附属杨浦医院) |
||||||||||||||||||||||
|
Primary sponsor: |
Shanghai Yangpu District Central Hospital (Tongji University Affiliated Yangpu Hospital) |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市杨浦区腾跃路 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Tengyue Road, Yangpu District, Shanghai |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
项目经费 |
||||||||||||||||||||||
|
Source(s) of funding: |
Project funds |
||||||||||||||||||||||
|
Target disease: |
primary dysmenorrhea |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
I期临床试验 | ||||||||||||||||||||||
|
Study phase: |
1 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
通过探究灭活肌筋膜触发点对原发性痛经的即刻和中长期疗效,并从神经肌肉功能和脑功能变化的角度探究处理腹部肌筋膜触发点对痛经的可能作用机制。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study investigates the immediate and long-term effects of inactivating myofascial trigger points on primary dysmenorrhea, and explores the potential mechanisms of treating abdominal myofascial trigger points for dysmenorrhea from the perspectives of neuromuscular function and brain function changes. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
①符合上述PDM的诊断标准者; ②年龄在18-35 岁之间; ③VAS评分在4分以上; ④月经周期规律者; ⑤治疗前1个月内未服用任何止痛药物; ⑥愿意接受腹部针刺治疗和愿意配合完成本次实验的相关程序。 |
||||||||||||||||||||||
|
Inclusion criteria |
1.Those who meet the above diagnostic criteria for PDM; 2.Aged between 18-35 years old; 3. Those with a VAS score of 4 or more; 4. Those who have regular menstrual cycles; 5. Those who have not taken any pain-relieving drugs within 1 month before treatment; 6.Willing to accept abdominal acupuncture treatment and willing to cooperate in completing the relevant procedures of this experiment. |
||||||||||||||||||||||
|
排除标准: |
①诊断为继发性痛经,或存在盆腔炎、子宫内膜异位症、子宫肌瘤等器质性病变; ②合并肝、肾、造血系统、心血管系统等严重原发性疾病或精神病; ③同时接受与本病治疗有关的其他治疗方法; ④触发点部位皮肤有感染及凝血功能异常; ⑤其他:未按本临床试验规定治疗,中途退出等。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Diagnosis of secondary dysmenorrhea, or the presence of organic pathologies such as pelvic inflammatory disease, endometriosis, uterine fibroids, etc; 2.Combination of serious primary diseases such as liver, kidney, hematopoietic system, cardiovascular system, or mental illness; 3.Concurrently receiving other treatments related to the treatment of this disease; 4.Infection of the skin at the trigger point site and abnormal coagulation function; 5.Others: not treated according to the provisions of this clinical trial, withdrawing halfway, etc |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-01-01 00:00:00至 To 2025-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2023-04-02 00:00:00 至 To 2025-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由不参与本次实验干预过程及结果评估的人员使用 SPSS 23.0 统计软件生成随机序列,并将生成的数字随机放入密封的信封中交给实验人员,受试者再签署完知情同意书后,根据入组顺序依次抽取信封确定最终分组,所有的实验人员和数据统计人员均不知晓信封中的数字,以保证分配的随机性和分配隐藏性。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
A random sequence was generated by a person who was not involved in the intervention process and outcome assessment of this experiment using SPSS 23.0 statistical software, and the generated numbers were randomly placed in sealed envelopes and given to the experimenters, and after the subjects had signed the informed consent form again, the envelopes were drawn sequentially according to the order of enrollment to determine the final grouping, and all of the experimenters and statisticians were unaware of the numbers in the envelopes to ensure that the allocation of the randomization and allocation concealment. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
在试验期间,所有数据采集和干预均由未知晓组别和研究内容的研究人员进行,受试者也不知晓各组的分配情况和干预方式,同时,数据录入和统计分析由不知晓本研究内容的研究人员完成。 |
|
Blinding: |
During the trial, all data collection and interventions are carried out by researchers who are unaware of the group assignments and study details. Participants are also unaware of the group allocation and the nature of the intervention. Meanwhile, data entry and statistical analysis are performed by researchers who are not informed about the study content. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
试验完成后6个月内公开 ,公开内容如原始记录的数据和研究计划书; (2)采用临床试验公共管理平台并向公众开放查询,或感兴趣者向研究者发邮件联系索取。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Within 6 months after the completion of the trial, the public , public content such as the original recorded data and study plan; (2) the use of clinical trial public management platform and open to the public query, or interested parties to contact the investigator by e-mail to obtain. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表和基于互联网的 EDC系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case record forms and Internet-based EDC systems |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |